Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on May 20 and 21, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold 2,000 shares of common stock on May 20, 2025, at a weighted average price of $11.25.
• He also sold 2,000 shares of common stock on May 21, 2025, at a weighted average price of $10.83.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Ma directly owns no shares, but indirectly owns 2,810,824 shares through his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of trading on material non-public information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, depending on how the market interprets the insider's actions.

Key Dates

Keywords

Form 4, Gyre Therapeutics, Songjiang Ma, Stock Sale, 10b5-1 Trading Plan, Insider Trading